A Phase II Study of ZD6474 (Vandetanib) in Patients With Von Hippel Lindau Disease and Renal Tumors
Phase of Trial: Phase II
Latest Information Update: 06 Nov 2018
At a glance
- Drugs Vandetanib (Primary)
- Indications Renal cancer; Von Hippel-Lindau disease
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 06 Apr 2015 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
- 05 Sep 2014 Planned End Date changed from 1 Aug 2014 to 1 Aug 2016, as reported by the ClinicalTrials.gov record.